PetMed Express (NASDAQ:PETS) Issues Quarterly Earnings Results

Posted by Francis Steltz on Aug 13th, 2026

PetMed Express (NASDAQ:PETS – Get Free Report) released its earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.40), FiscalAI reports. PetMed Express had a negative net margin of 32.00% and a negative return on equity of 76.86%. The company had revenue of $41.02 million during the quarter, compared to analysts’ expectations of $71.00 million.

PetMed Express Stock Performance

PetMed Express stock traded up $0.02 during mid-day trading on Thursday, reaching $2.03. The company’s stock had a trading volume of 199,057 shares, compared to its average volume of 345,090. The firm’s fifty day moving average price is $1.90 and its two-hundred day moving average price is $2.31. PetMed Express has a 12-month low of $1.57 and a 12-month high of $4.10. The company has a market capitalization of $43.39 million, a P/E ratio of -0.74 and a beta of 0.76.

Hedge Funds Weigh In On PetMed Express

A number of large investors have recently made changes to their positions in PETS. Occudo Quantitative Strategies LP purchased a new position in shares of PetMed Express in the second quarter valued at $51,000. Oxford Asset Management LLP purchased a new stake in PetMed Express during the 2nd quarter worth about $55,000. Jain Global LLC bought a new position in PetMed Express in the 4th quarter worth about $78,000. CIBC Private Wealth Group LLC purchased a new position in PetMed Express during the 3rd quarter valued at about $75,000. Finally, Goldman Sachs Group Inc. increased its position in shares of PetMed Express by 59.3% during the first quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock valued at $139,000 after buying an additional 12,360 shares during the period. 73.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PETS shares. Zacks Research upgraded shares of PetMed Express to a “hold” rating in a research note on Thursday, April 30th. Weiss Ratings raised PetMed Express from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen raised PetMed Express from a “strong sell” rating to a “hold” rating in a research report on Saturday, June 6th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

Get Our Latest Report on PetMed Express

PetMed Express Company Profile

(Get Free Report)

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.